Related Experiment Video

Updated: Jun 16, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Long-term efficacy of pravastatin therapy in diabetic patients undergoing complete coronary revascularization

Kouichiro Aihara1, Katsumi Miyauchi, Takatoshi Kasai

  • 1Department of Cardiovascular Medicine, Juntendo University, School of Medicine, Tokyo, Japan.

Journal of Atherosclerosis and Thrombosis
|February 16, 2010
PubMed

Insights

Statin therapy after coronary revascularization significantly reduced cardiac mortality in diabetic patients. This finding highlights the importance of statins for improving outcomes in this high-risk population.

Area of Science:

  • Cardiology
  • Pharmacology
  • Diabetology

Background:

  • The long-term impact of statin therapy in diabetic patients following coronary revascularization remains unclear.
  • Complete revascularization, including percutaneous coronary intervention (PCI) and/or bypass surgery, is a standard treatment for coronary artery disease.

Purpose of the Study:

  • To investigate the effect of statin therapy initiated during complete revascularization on total and cardiac mortality in diabetic patients.
  • To assess the long-term benefits of statins in this specific patient cohort.

Main Methods:

  • A cohort of 1,138 patients undergoing complete revascularization was analyzed.
  • Mortality rates were compared between 499 diabetic patients, with 149 receiving statin therapy at revascularization.
  • Propensity score and multivariate Cox regression were used to adjust for confounding variables.

Main Results:

  • Over an average follow-up of 8.8 years, statin therapy was significantly associated with reduced cardiac mortality (HR 0.39; p=0.039).
  • No significant association was found between statin therapy and reduced all-cause mortality.
  • 43 cardiac deaths and 103 total deaths occurred during the study period.

Conclusions:

  • Statin therapy initiated at the time of complete revascularization significantly reduces cardiac mortality in diabetic patients.
  • These findings support the use of statins to improve cardiovascular outcomes in diabetic patients with coronary artery disease post-revascularization.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...